KLRK1 and Miyoshi myopathy: Thus, a bispecific immunoligand, which consists of the natural NKG2D-ligand ULBP2 fused to a scFv targeting CD138 expressed on multiple myeloma (MM) cells, showed promising results in vitro and in a xenograft mouse model (32).